NOK
Nokia Oyj
NOK has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over NOK overall, supported by stronger fundamentals and stronger modeled upside.
NOK Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Under pressure | |
| Strong |
NOK's profitability and balance sheet are currently healthy, and its revenue is stable, but its cash flow is under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
NOK PE Valuation
NOK has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
NOK Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for NOK, with profitability improving. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
NOK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.15 | +67% |
| Q2 2026 | $0.14 | +27% |
| Q1 2026 | $0.16 | +220% |
| Q4 2025 | $0.13 | -13% |
| Q3 2025 | $0.09 | +13% |
| Q2 2025 | $0.11 | +57% |
| Q1 2025 | $0.05 | -69% |
| Q4 2024 | $0.15 | +15% |
NOK has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
NOK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.7B | +6.1% |
| Q2 2026 | $5.3B | +5.9% |
| Q1 2026 | $5B | +2.4% |
| Q4 2025 | $6.8B | +2.4% |
| Q3 2025 | $5.4B | +12% |
| Q2 2025 | $5.1B | +1.8% |
| Q1 2025 | $4.9B | -1.2% |
| Q4 2024 | $6.6B | +4.9% |
NOK's revenue is recovering but still below its 2022 peak: $5.7B last quarter, up 6.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 17% | +12 points |
| Q2 2026 | -1% | -2.8 points |
| Q1 2026 | 1.4% | +2.5 points |
| Q4 2025 | 7.1% | -0.8 points |
| Q3 2025 | 5% | -1.5 points |
| Q2 2025 | 1.8% | -7.9 points |
| Q1 2025 | -1.1% | -10 points |
| Q4 2024 | 7.9% | -1.6 points |
NOK has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over NOK on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
NOK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$112M | -123% |
| Q2 2026 | -$832.1M | -951% |
| Q1 2026 | $698.8M | -13% |
| Q4 2025 | $252.2M | +354% |
| Q3 2025 | $476.6M | -37% |
| Q2 2025 | $97.8M | -78% |
| Q1 2025 | $801M | -25% |
| Q4 2024 | $55.5M | -97% |
NOK usually generates cash, though not every quarter: the latest was −$112M, but it generated $7M over the past year.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over NOK on cash flow, with more consistent year-over-year improvement.
NOK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1% | -56.5M shares |
| 1 year | +4.7% | +257M shares |
| 3 years | +2.6% | +148M shares |
| 5 years | +0.9% | +54M shares |
| Available history | +2.2% | +123M shares |
NOK has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | $10M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $86.7M |
| Q1 2025 | $606.6M |
| Q4 2024 | $428.8M |
NOK has spent almost nothing on buybacks in the past year.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
NOK Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.3x | Net Cash |
| Q2 2026 | -0.5x | Net Cash |
| Q1 2026 | -0.7x | Net Cash |
| Q4 2025 | -0.1x | Net Cash |
| Q3 2025 | -0.3x | Net Cash |
| Q2 2025 | -0.3x | Net Cash |
| Q1 2025 | -0.2x | Net Cash |
| Q4 2024 | -0.5x | Net Cash |
NOK has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over NOK on leverage, with a lower net debt burden relative to earnings.
NOK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.8 | Neutral |
| Stochastic | 18.3 | Oversold |
NOK's weekly RSI is 41 (neutral) and its Stochastic is 18 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
NOK PE vs Technology Sector
| Metric | NOK | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 28x | — |
NOK has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
NOK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $9.14 | 9.4% below |
| 20 week MA | $9.92 | 17% below |
| 50 week MA | $9.66 | 14% below |
| 100 week MA | $7.35 | 13% above |
| 200 week MA | $5.67 | 46% above |
NOK has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 46% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over NOK on trend strength, trading above more of its moving averages.
NOK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $3.63 | $3.89 | +7.2% |
| 2021 | $3.89 | $6.19 | +59% |
| 2022 | $6.19 | $4.64 | -25% |
| 2023 | $4.64 | $3.42 | -26% |
| 2024 | $3.42 | $4.48 | +31% |
| 2025 | $4.48 | $6.62 | +48% |
| 2026 YTD | $6.62 | $8.28 | +25% |
NOK has finished higher in four of the last six years. It's up 25% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over NOK on returns for 2026, with the stronger performance.